Seegene, Inc. (096530.KQ)
KRW 26500.0
(0.76%)
KRW 26500.0
(0.76%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 367.37 Billion KRW | -56.96% |
| 2022 | 853.56 Billion KRW | -37.73% |
| 2021 | 1370.83 Billion KRW | 21.83% |
| 2020 | 1125.21 Billion KRW | 822.66% |
| 2019 | 121.95 Billion KRW | 19.25% |
| 2018 | 102.26 Billion KRW | 15.01% |
| 2017 | 88.91 Billion KRW | 20.66% |
| 2016 | 73.69 Billion KRW | 13.14% |
| 2015 | 65.13 Billion KRW | 1.13% |
| 2014 | 64.41 Billion KRW | 9.18% |
| 2013 | 58.99 Billion KRW | 14.08% |
| 2012 | 51.71 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 89.94 Billion KRW | -10.51% |
| 2024 Q2 | 100.13 Billion KRW | 11.33% |
| 2023 Q2 | 84.92 Billion KRW | -5.69% |
| 2023 Q1 | 90.04 Billion KRW | -26.68% |
| 2023 FY | 367.37 Billion KRW | -56.96% |
| 2023 Q4 | 100.51 Billion KRW | 9.39% |
| 2023 Q3 | 91.88 Billion KRW | 8.19% |
| 2022 Q3 | 150.84 Billion KRW | 17.44% |
| 2022 Q2 | 128.44 Billion KRW | -71.55% |
| 2022 Q4 | 122.82 Billion KRW | -18.58% |
| 2022 Q1 | 451.45 Billion KRW | 10.1% |
| 2022 FY | 853.56 Billion KRW | -37.73% |
| 2021 Q1 | 351.75 Billion KRW | -20.37% |
| 2021 Q3 | 305.3 Billion KRW | 0.52% |
| 2021 FY | 1370.83 Billion KRW | 21.83% |
| 2021 Q4 | 410.03 Billion KRW | 34.3% |
| 2021 Q2 | 303.73 Billion KRW | -13.65% |
| 2020 Q1 | 81.77 Billion KRW | 142.1% |
| 2020 Q3 | 326.87 Billion KRW | 18.94% |
| 2020 Q4 | 441.73 Billion KRW | 35.14% |
| 2020 FY | 1125.21 Billion KRW | 822.66% |
| 2020 Q2 | 274.83 Billion KRW | 236.1% |
| 2019 FY | 121.95 Billion KRW | 19.25% |
| 2019 Q3 | 31.39 Billion KRW | 7.16% |
| 2019 Q4 | 33.77 Billion KRW | 7.57% |
| 2019 Q2 | 29.29 Billion KRW | 6.62% |
| 2019 Q1 | 27.47 Billion KRW | -9.21% |
| 2018 Q1 | 23.88 Billion KRW | -8.06% |
| 2018 FY | 102.26 Billion KRW | 15.01% |
| 2018 Q4 | 30.26 Billion KRW | 29.6% |
| 2018 Q3 | 23.35 Billion KRW | -5.67% |
| 2018 Q2 | 24.75 Billion KRW | 3.66% |
| 2017 Q3 | 20.06 Billion KRW | -9.02% |
| 2017 Q2 | 22.05 Billion KRW | 5.91% |
| 2017 Q1 | 20.82 Billion KRW | 3.34% |
| 2017 Q4 | 25.97 Billion KRW | 29.48% |
| 2017 FY | 88.91 Billion KRW | 20.66% |
| 2016 FY | 73.69 Billion KRW | 13.14% |
| 2016 Q1 | 17.23 Billion KRW | 1.51% |
| 2016 Q2 | 18.52 Billion KRW | 7.48% |
| 2016 Q3 | 17.78 Billion KRW | -3.95% |
| 2016 Q4 | 20.15 Billion KRW | 13.27% |
| 2015 Q2 | 16.45 Billion KRW | -0.08% |
| 2015 Q1 | 16.46 Billion KRW | 5.06% |
| 2015 Q4 | 16.97 Billion KRW | 11.37% |
| 2015 FY | 65.13 Billion KRW | 1.13% |
| 2015 Q3 | 15.24 Billion KRW | -7.35% |
| 2014 Q1 | 17.06 Billion KRW | 4.78% |
| 2014 FY | 64.41 Billion KRW | 9.18% |
| 2014 Q4 | 15.67 Billion KRW | 4.85% |
| 2014 Q3 | 14.94 Billion KRW | -10.61% |
| 2014 Q2 | 16.72 Billion KRW | -2.04% |
| 2013 Q4 | 16.29 Billion KRW | 8.18% |
| 2013 Q2 | 14.17 Billion KRW | 5.26% |
| 2013 FY | 58.99 Billion KRW | 14.08% |
| 2013 Q3 | 15.05 Billion KRW | 6.23% |
| 2013 Q1 | 13.46 Billion KRW | -16.33% |
| 2012 Q4 | 16.09 Billion KRW | 29.21% |
| 2012 Q3 | 12.45 Billion KRW | 0.0% |
| 2012 FY | 51.71 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 355.84 Billion KRW | -3.24% |
| InBody Co.,Ltd | 170.35 Billion KRW | -115.657% |
| Curexo Inc. | 72.88 Billion KRW | -404.067% |
| i-SENS, Inc. | 265.12 Billion KRW | -38.569% |
| Ray Co., Ltd. | 145.88 Billion KRW | -151.831% |
| Gencurix Inc. | 2.6 Billion KRW | -14028.083% |
| Sugentech Inc. | 7.13 Billion KRW | -5050.86% |
| L&C Bio Co., Ltd | 68.86 Billion KRW | -433.436% |